

References

I-209

1. S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences. (2019). Genetic and Rare Diseases (GARD) Information Center.
2. Micromedex®Solutions Compendia. 2020. Emapalumab-lzsg.
3. Emapalumab-lzsg. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
4. Gamifant™ (emapalumab-lzsg) injection, for intravenous use [package insert]. Sobi, Inc. Waltham, MA. Revised 11/2018.
5. Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. *Medicine*. 2018;97(31):1-9.
6. Jordan MB. Emergence of targeted therapy for hemophagocytic *American Society of Hematology*. 2018;15(2):1-8.
7. Louder DT, Bin Q, de Min C, et al. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. *Blood Advances*. 2019; 3(1):47-50.
8. Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. *Blood*. 2019;134(21):1783-1786.
9. Al-Salama ZT. Emapalumab: first global approval. *Drugs*. 2019;79(99): 103-108.